The Alliance for Longevity Initiatives (A4LI)

𝗠𝗮𝗿𝗸 𝗬𝗼𝘂𝗿 𝗖𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀! 𝗢𝘂𝗿 𝗗.𝗖. 𝗦𝘂𝗺𝗺𝗶𝘁 𝗿𝗲𝘁𝘂𝗿𝗻𝘀 — 𝗿𝗲𝗶𝗺𝗮𝗴𝗶𝗻𝗲𝗱 𝗮𝗻𝗱 𝗿𝗲𝗯𝗿𝗮𝗻𝗱𝗲𝗱 𝗮𝘀 𝘁𝗵𝗲 𝗕𝗶𝗴𝗴𝗲𝗿, 𝗕𝗼𝗹𝗱𝗲𝗿 𝗛-𝗦𝗽𝗮𝗻 𝗦𝘂𝗺𝗺𝗶𝘁, 𝗶𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗯𝘆 𝗼𝘂𝗿 𝗛-𝗦𝗽𝗮𝗻 𝗣𝗼𝗱𝗰𝗮𝘀𝘁. We’re thrilled to partner with Georgetown University Medical Center to host the H-Span Summit D.C., June 29–July 1, 2026 at Georgetown University’s Capitol Campus, followed by Hill Day on Capitol Hill. Now in its third year, the newly renamed H-Span Summit has quickly become the nation’s leading forum for advancing America’s healthspan and longevity policy agenda. 📢 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲: a4li.org/wp-content/upl… 🌟 𝟮𝟬𝟮𝟲 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 🧬 Day 1 — Scientific Advancement in the Longevity Landscape Cutting-edge research in aging biology, therapeutics, and emerging technologies reshaping human healthspan. 🏛️ Day 2 — Building the Framework: Policy Levers for Longevity Innovation Policymakers, Longevity Science Caucus members, and top experts outline pathways to accelerate longevity innovation. 📣 Day 3 — Congressional Briefing & Hill Day A4LI leads its largest-ever effort to elevate healthy lifespan as a national priority. 🎟️ Secure your early bird ticket today: a4li.org/h-span-summit-…

Huge shoutout to my friend Ken Coit for stepping up to support a major gap in longevity research. Excited to be advising this world-class team at @UAZPharmacy on what could become a landmark clinical trial of rapamycin in humans. We still have far more questions than answers about rapamycin and human aging—but this is exactly the kind of rigorous study we need to move the field forward. If successful, it could meaningfully shape how we think about targeting aging biology in people. news.arizona.edu/news/u-launche…

We are thrilled to welcome Brian Norman, Director of State Affairs at the @GoldwaterInst, for a fireside chat at H-SPAN Arizona. While the original Right to Try Act opened doors for terminal patients, Brian is now leading the charge on Right to Try 2.0, pioneering a pathway for individualized, "N-of-1" treatments. These personalized gene therapies and immunotherapies often don't fit the traditional FDA clinical trial mold, yet they represent the future of medical intervention in the aging-biology ecosystem. This conversation will dive into how we can modernize our regulatory frameworks to support the next generation of geroscience innovation. Don't miss this deep dive into the policies that will define the future of patient access. We look forward to having you join us! As an AZ Tech Week program, please register on Partiful: partiful.com/e/trmLrsuHDWm4… @azcommerce @AZTechWeek

Next week, we’re excited to feature a special fireside chat with Dr. Rick Schnellmann at H‑SPAN Arizona, highlighting one of the most respected voices in renal pharmacology, drug discovery, and the translation of aging‑related biology into real therapeutic impact. Dr. Schnellmann — the Howard J. Schaeffer Endowed Chair in Pharmaceutical Sciences at the University of Arizona (@UAZPharmacy) has spent his career uncovering how cellular injury, mitochondrial dysfunction, and metabolic resilience shape health across the lifespan. His work has been continuously funded for nearly four decades and has led to multiple biotech spin‑outs advancing new treatments for kidney injury, neurodegeneration, and metabolic disease. This will be a rare, candid look at the scientific, translational, and leadership journey behind one of the field’s most influential researchers, and we’re beyond grateful to be highlighting it at our event. We look forward to having you join us! As an AZ Tech Week program, please register on Partiful: partiful.com/e/trmLrsuHDWm4… @azcommerce @UAZPharmacy @uazmedphx @UAZHealth @AZTechWeek

We’re honored to have Rep. David Schweikert (@RepDavid) join us at H-SPAN Arizona for opening remarks as we begin a full day focused on aging biology, innovation, and Arizona’s growing leadership in this field. In addition to representing the district that includes the Scottsdale Airpark innovation corridor, Rep. Schweikert serves on the Joint Economic Committee and the Ways & Means Social Security Subcommittee. He has been a leading voice on how emerging technologies — from AI to biotechnological breakthroughs can strengthen the economy and improve healthcare delivery. Crucially, his work emphasizes how these innovations are vital tools for addressing Social Security solvency and the fiscal challenges of an aging population. By leveraging data and new tools to extend healthspan, we can better prepare for demographic shifts and rising healthcare costs—themes that resonate deeply with the aging-biology ecosystem. We’re grateful he’ll help us open the day before we transition into a program led by researchers, founders, and innovators advancing the future of healthspan. @AZTechWeek | @azcommerce | @VensureHR | @ZuberLawler

Have you thought about the politics of longevity? Today’s guest on the @FreeRadicalsBio podcast is Dylan Livingston (@dullunlivin), the 28 year old founder of the Alliance for Longevity Initiatives @theA4LI. Dylan created America’s first and only lobbying group focused on advancing longevity initiatives in Washington DC. Since its founding, A4LI has created a longevity caucus composed of 8 congresspeople, and hosted leaders like Dr. Oz, Newt Gingrich and @mkaeberlein at their summits. A4LI also played a key role in garnering bipartisan support to advance Montana’s Right to Try legislation, which expands the right for consenting patients to utilize safe experimental medicines in Montana. In this episode, we discuss how Dylan gets bipartisan support for healthy life extension initiatives, what it’s like selling politicians on longevity, and A4LI’s role in accelerating longevity towards its ChatGPT moment. Follow me and @EricDai_BioE for weekly episodes about longevity biotech! 0:00 Intro 1:52 Origin story of the first longevity lobby 10:30 State of government support for longevity 14:49 Trump administration’s view on longevity 17:30 The unique policy needs of longevity biotech 23:42 A4LI’s success with right to try 30:30 Why lobbying is so effective for accelerating longevity 34:32 Case for optimism in longevity & the need for more investment 40:04 What arguments resonate with congresspeople 49:23 Bryan Johnson’s impact on the perception of longevity 52:15 Who are the most important people to influence

This week on A4LI’s Scientist Spotlight, we speak with Dr. Blaise Mariner, a bioinformatician researcher with the Snyder-Mackler Lab at @ASU and the @DogAgingProject. In this episode, we discuss his path from engineering to aging biology, the questions driving his research, and how large-scale datasets are helping uncover the molecular signatures of aging. You can listen to the full episode here: a4li.org/podcast/scient…

We’re spotlighting the breakthroughs happening right in Arizona, #1 in the nation for startup spin‑outs from academic research. And if your discovery pipeline runs on AI… Arizona isn’t just cheering you on — they’re manufacturing your chips! Our panel — AI in Data & Innovation will be moderated by Tom Zuber, JD (Managing Partner, @ZuberLawler), whose work sits at the intersection of emerging technology, intellectual property, and the legal frameworks shaping responsible innovation. He’ll be joined by three leaders pushing the frontier of AI‑driven discovery, data infrastructure, and real‑world application: Sami Mian, PhD (Chief AI Officer, @VensureHR) — A seasoned inventor and leader who has guided large-scale AI and robotics initiatives across industry and government. @ASU Pierre‑Alexandre Fournier (CEO, @Hexoskin) — pioneering biometric sensing, continuous monitoring, and data platforms that unlock new insights into human performance and health. Ruchir Sehra, MD, MBA (Medtech Executive Consultant) — guiding medtech and digital‑health companies in deploying AI, predictive modeling, and clinical‑grade data tools to accelerate innovation. @ASU Together, they’ll explore how AI is reshaping data pipelines, powering next‑generation discovery, and enabling smarter, more personalized approaches across health, enterprise, and technology. More speaker highlights coming soon as we count down to H‑SPAN Arizona: partiful.com/e/trmLrsuHDWm4…. @AZTechWeek

Yesterday we hosted FRS speaker Dr. Catherine Kaczorowski who gave an outstanding seminar on the role of dietary restriction and genetic determinations on cognition. Thank you Dr. Kaczorowski!

One of the most anticipated conversations at H‑SPAN Arizona brings together leaders translating aging biology into real‑world healthspan gains. Our panel — Extending Healthspan by Targeting the Biology of Aging — will be moderated by Dr. Noah Snyder‑Mackler (ASU), whose work illuminates how environment, stress, and molecular pathways shape aging trajectories. He’ll be joined by three innovators pushing the frontier of geroscience: Eric Morgen | @eric_k_morgen (COO, @bioagelabs) — advancing therapeutics that leverage human aging‑omics to target the pathways most critical for resilience and metabolic health. Dr. Brianna Stubbs | @BriannaStubbs (@BuckInstitute) — leading translational programs that bridge metabolism, biomarkers, and interventions to improve healthspan. Dr. Zachary Brooks (UGenome) — developing genomic and AI‑driven tools to understand individual aging patterns and unlock personalized longevity strategies. @UAZTechLaunch Together, they’ll explore where the science is strongest, where translation is accelerating, and what it will take to bring aging‑targeted interventions to patients. This is the moment where biology, biotech, and real‑world impact converge — and Arizona is hosting the conversation. More speaker highlights coming soon as we count down to H‑SPAN Arizona: partiful.com/e/trmLrsuHDWm4…. @AZTechWeek

We’re opening H‑SPAN Arizona with the foundation that drives everything in longevity: cutting‑edge academic research featuring: Dr. George Sutphin (@senmorteco) (Associate Professor, @UAZBIO5, University of Arizona) — advancing genetic and pharmacological approaches to extend lifespan and healthspan. Dr. Noah Snyder‑Mackler (Professor, School of Life Sciences and Center for Evolution and Medicine, @ASU) — uncovering the molecular and environmental drivers of aging using multi‑omics and primate models. Dr. Bonnie LaFleur (Director, Health Outcomes & PharmacoEconomics Center, University of Arizona @uazresearch) — pioneering biostatistical and biomarker frameworks that translate aging science into precision‑health applications. Together, they’ll highlight the newest directions emerging from Arizona’s academic labs — from cellular mechanisms to translational pathways and set the scientific foundation for the biotech, innovation, and policy discussions that follow throughout the day. Starting with the science is intentional. It grounds the event in rigor, showcases Arizona’s growing leadership in geroscience, and spotlights the researchers pushing the field forward. More speaker highlights coming soon as we count down to H‑SPAN Arizona: partiful.com/e/trmLrsuHDWm4…. @AZTechWeek

Following a unanimous 100-0 Senate vote on March 3rd, the U.S. House of Representatives officially passed S. 3971 today in a 345-41 landslide today. The bill now heads to the President’s desk to reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through September 30, 2031. For the geroscience community, this reauthorization is more than just a policy extension—it is a lifeline. SBIR/STTR grants provide critical non-dilutive funding, allowing founders to retain equity while de-risking high-frontier science. This capital is often the only bridge across the "Valley of Death" that precarious gap between laboratory discovery and commercial viability where so many breakthrough therapies stall due to a lack of early-stage private investment. Several longevity‑focused companies have successfully utilized these programs to advance their pipelines, including CyclarityTx, Juvena Therapeutics, and Vincere Biosciences. By securing this 6-year extension, Congress is ensuring that the next wave of aging-biology startups has a stable runway to turn research into real-world healthspan solutions. The Alliance for Longevity Initiatives (A4LI) is proud to have been a consistent, leading voice on the Hill in support of these programs. We thank the members of the House and Senate for recognizing that the future of American health and economic security starts with our small business innovators.

Yesterday in the New Hampshire House we passed HB 1735, legislation I introduced to expand access to life saving medical treatments for patients battling rare diseases and severe medical conditions. This bill builds directly on the Right to Try law championed last year by Rep Lisa Mazur. Her legislation created a pathway for terminally ill patients to access investigational treatments. HB 1735 expands that framework so more patients suffering from rare and severe diseases can pursue promising therapies under the care of their physicians when traditional treatments have failed. This is especially important because New Hampshire is already home to companies and researchers doing groundbreaking work such as growing bone, regenerating cartilage, and repairing tissue using a patient’s own cells. These innovations have the potential to change lives. Without legislation like HB 1735, many of these treatments could not move forward here in New Hampshire. Patients would be forced to travel to another state or even leave the country to access procedures that could save or dramatically improve their lives. HB 1735 helps ensure New Hampshire remains a place where medical innovation thrives and where patients are given every possible chance to fight for their lives.

The Alliance for Longevity Initiatives (A4LI) would like to applaud the passage of HB1734 and HB1735 in the New Hampshire House of Representatives, two groundbreaking pieces of legislation designed to expand patient access to cutting-edge medical treatments and accelerate the development of next-generation therapies. Together, these bills represent a major step toward making New Hampshire a national leader in biomedical innovation and patient access to promising therapies. The legislation builds on reforms A4LI advocated for in Montana, where policymakers previously enacted similar policies designed to expand access to experimental therapies while encouraging biomedical innovation. We look forward to keeping you all updated as both pieces of legislation now advance to the New Hampshire Senate for consideration.